Dunne MW, Havlir D, Dube M, Sattler F, Forthal D, Kemper C, McCutchan A; International Conference on AIDS.
Int Conf AIDS. 1996 Jul 7-12; 11: 236 (abstract no. Tu.B.410).
Pfizer Central Research, Groton, CT, USA.
Animal models have demonstrated synergistic effects of azithromycin and sulfamethoxazole in the prevention of Pneumocystis carinii pneumonia (PCP). In order to determine whether similar effects could be seen in the setting of HIV infection, the incidence of PCP was determined for patients enrolled in a randomized, double blinded trial comparing azithromycin (1200 mg once weekly), rifabutin (300 mg daily) and the combination of both for the prophylaxis of Mycobacterium avium infection for a mean duration of approximately one year. 97% of all patients were taking prophylaxis for PCP. Data is analyzed on an intent to treat basis for all subjects who took study drug and includes events occurring within 30 days of the last dose. The diagnosis of PCP was made by the investigator either empirically or by recovery of the organism. (table: see text) For patients who received greater than or equal to one dose of sulfamethoxazole or dapsone during the trial, the incidence of PCP was 8.7% on azithromycin containing regimens compared to 13.0% on rifabutin. In addition to its efficacy in the prevention of disseminated MAC, azithromycin in concert with other PCP prophylaxis regimens, reduces the risk of developing PCP by one half in HIV-infected subjects with less than 100 CD4 cells/mm3.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Azithromycin
- Dapsone
- Drug Therapy, Combination
- HIV Infections
- Humans
- Mycobacterium avium-intracellulare Infection
- Pneumonia, Pneumocystis
- Rifabutin
- Sulfamethoxazole
- Trimethoprim-Sulfamethoxazole Combination
- drug therapy
- therapy
Other ID:
UI: 102217972
From Meeting Abstracts